Global Amyotrophic Lateral Sclerosis Treatment Market Research Report: Forecast (2025-2030)

Market Definition

Amyotrophic lateral sclerosis (ALS) is a neurological disorder that causes damage to brain and spinal cord nerve cells. Muscle control loss causes ALS to worsen over time. As the disease progresses ALS patients may experience breathing difficulties and lose the ability to move their arms and legs. Nerve cells in ALS die which stops them from communicating with muscles. Early signs include mild speech and muscle issues such as difficulty in writing or walking.

Market Insights & Analysis: Global Amyotrophic Lateral Sclerosis Treatment Market (2025-2030)

The Global Amyotrophic Lateral Sclerosis Treatment Market size was valued at around USD 0.72 billion in 2024 and is projected to reach USD 0.97 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 5.1% during the forecast period, i.e., 2025-30. Several factors support this growth. The market is expanding as a result of more funding and investments made by different organizations. Amyotrophic Lateral Sclerosis is becoming more prevalent worldwide which is driving the market toward new prospects.

*Boost strategic growth with in-depth market analysis - Get a free sample preview today!

Additionally, pipeline medications and treatments along with technological developments in diagnostics are attempting to meet the market’s increasing demand. Moreover, ALS researchers, hospitals, and manufacturers are receiving subsidies and investments from government programs and other regulatory factors which will ultimately accelerate market growth.Since, there is currently no cure for ALS, the need for new and improved therapies is increasing drastically. Numerous governmental and non-governmental organizations worldwide are focusing on the management and treatment of amyotrophic lateral sclerosis. Governments around the world are funding research into the causes and treatments of ALS. Through its Hoffman ALS Clinical Trial Awards 2023, the ALS Association has committed nearly USD 4 million to support four early-stage clinical trials.

The US government included USD 200 Million for Amyotrophic Lateral Sclerosis Research & Programs in their fiscal budget 2022. To support preclinical & clinical research the National Institute of Health seeks funding of around USD 160 Million in 2025. The ALS market will grow as a result of this as it will assist researchers in gaining a deeper understanding of the illness and creating new treatment strategies. New treatments can be quickly introduced to the market, with increased funding which also supports early-phase clinical trials and speeds up the approval pipeline. This will help ALS researchers to further develop insights into the disease and develop novel treatment approaches, fueling growth in the ALS market. The rise in funding also supports early-phase clinical trials and accelerates the approval pipeline, rapidly bringing new therapies to the market.

Global Amyotrophic Lateral Sclerosis Treatment Market Driver:

Growing Prevalence of Amyotrophic Lateral Sclerosis – The rising cases of amyotrophic lateral sclerosis worldwide are one of the main factors that drive the market for this neurodegenerative condition. The disease is majorly growing in the North American region more likely to affect Whites and non-Hispanics. It is anticipated that the prevalence of amyotrophic lateral sclerosis will slightly increase as a result of the aging population, early diagnosis, and greater global awareness. Approximately 5,000 cases of amyotrophic lateral sclerosis are diagnosed every year in the US. Although it is a rare disease still the global prevalence rate of ALS is around 4–6 cases per 100,000 individuals. Furthermore, males have a higher prevalence than females comparatively but in old age, they are equally likely to be diagnosed with ALS. Sporadic ALS is making up to 90-95% of the total cases globally. Thus, the prevalence of ALS will continue to drive market growth during the forecast period.

Global Amyotrophic Lateral Sclerosis Treatment Market Opportunity:

Pipeline and Drug Therapies – Gene therapies and regenerative medicine are gaining more attention from businesses and academic institutions which could lead to new treatment options and new opportunities for market growth. With encouraging results, medications that target SOD1 mutation accounting for about 2% of ALS cases, are currently in different clinical stages. Many potential treatments are under the clinical trials pipeline before seeking approval from the FDA.

More than 160 medications that address various aspects of the disease and span various stages of clinical trials were in the ALS pipeline by the end of 2023. Additionally, in 2023 the FDA approved seven additional medications to treat ALS. To introduce effective treatments to the market, several businesses including Mitsubishi Tanabe Pharma Corporation and Biogen are pursuing these opportunities.

Global Amyotrophic Lateral Sclerosis Treatment Market Challenge:

High Cost of Amyotrophic Lateral Sclerosis Treatment – The high expense of treating amyotrophic lateral sclerosis can cause serious restraints on market growth. Recently approved medication Qalsody which costs more than USD 14,230 per dose is used to treat ALS. With 13–14 doses annually, the treatment cost comes to about USD 199,200. For instance; the per year cost of Mitsubishi Tanabe’s Edaravone could reach up to USD 169,000. Without proper insurance and other support, it is almost impossible to opt for the treatment of ALS in both developing and underdeveloped nations. The annual cost associated with a person diagnosed with ALS can reach up to USD 250,000. Therefore, high costs may make it difficult for therapeutic drugs to be widely used and will diminish the market growth rate.

Global Amyotrophic Lateral Sclerosis Treatment Market Trend:

Technological Advancements in Diagnostics – Technological advancements in diagnostics are emerging as a key trend in the global ALS market because of the need for accurate and timely detection. Advancements in genetic testing biomarker discovery and advanced imaging techniques are improving the diagnosis of ALS by enabling quicker and more precise assessments. Significant progress in biomarker research has enabled the identification of potential markers such as neurofilament light chains in blood or cerebrospinal fluid. This might help with ALS early diagnosis. The application of neuroimaging technologies such as MRI with diffusion tensor imaging which helps detect structural and functional changes in the corticospinal tract and motor cortex regions affected by ALS is another advancement in diagnosis. For instance; Clene Nanomedicines’ creation of CNM-Au8 uses biomarkers and sophisticated neuroimaging to measure its effects on neuronal health and demonstrate how new technology helps evaluate therapeutic impacts on ALS.

Global Amyotrophic Lateral Sclerosis Treatment Market (2025-2030): Segmentation Analysis

The Global Amyotrophic Lateral Sclerosis Treatment Market study of MarkNtel Advisors evaluates & highlights the major trends and influencing factors in each segment. It includes predictions for the period 2025–2030 at the global. Based on the analysis, the market has been further classified as:

By End User

• Hospitals
• Rehabilitation Centers
• Specialty Clinics
• Others

Out of them, the hospital segment leads the Global Amyotrophic Lateral Sclerosis Treatment Market. It holds approx. 38% of the global market. They provide treatment through multidisciplinary treatment teams. They also offer complete care with the help of advanced diagnostics, and access to the newest therapies. Specialized services including physical therapy, respiratory support, and medication management are offered by the hospitals for ALS patients. Technology developments and a growing emphasis on integrated care strategies for ALS management are deriving segmental growth. Hospitals have become the top option for patients requiring critical care or experimental treatments such as clinical trials due to their ability to manage complex cases. The hospital segment will show substantial growth during the forecast period as well.

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

Out of them, hospital pharmacies lead the Global Amyotrophic Lateral Sclerosis Treatment Market. They hold approximately 58.4% share of the total market value. The complex and multidisciplinary treatment needs of ALS patients frequently need specialized care, continuous hospital stays, and a need for an easily accessible supply of ALS medications. Hospital pharmacies dominate this market because they offer a central location for patients who require close medical supervision and convenient access to necessary medications. Because of the possible adverse effects of ALS medications hospital pharmacies provide a controlled setting in which complex medications like; riluzole and edaravone can be precisely dispensed and administered. This guarantees that ALS patients receive precise dosages and prompt medical supervision. The hospital pharmacies segment is anticipated to grow during the forecast period as well.

Global Amyotrophic Lateral Sclerosis Treatment Market (2025-30): Regional Projections

Geographically, the Global Amyotrophic Lateral Sclerosis Treatment Market expands across:

• North America
• South America
• Europe
• The Middle East & Africa
• Asia-Pacific

Out of them, North America dominates the Global Amyotrophic Lateral Sclerosis Treatment Market. It holds approximately 55% share of the total market. High healthcare expenditures in the region coupled with the growing prevalence of the disease is boosting the demand for the ALS market. Also, the advanced healthcare infrastructure fulfills the additional requirement of the treatment. North America has a majority of old population and since the disease is more common in people with age above 50, treatments for amyotrophic lateral sclerosis become extremely important.

Furthermore, with advantageous reimbursement practices and the presence of large pharmaceutical companies in the region, innovations in necessary medications can reach to increasing number of patients. Growing awareness of ALS and ongoing research projects are driving the market expansion while establishing North America as a pioneer in ALS treatment advancements and enhancing patient outcomes.

 Global Amyotrophic Lateral Sclerosis Treatment Industry Recent Development:

• February 2024: Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group Corporation) launched Radicava for the treatment of ALS in Brazil at a local subsidiary of Daiichi Sankyo Company, Limited.
• April 2023: Biogen received approval from the European Commission for QALSODY (tofersen) Therapy that treats SOD1-ALS. It is the third targeted drug that has been approved for the treatment of ALS.

Gain a Competitive Edge with Our Global Amyotrophic Lateral Sclerosis Treatment Market Report:

1. Global Amyotrophic Lateral Sclerosis Treatment Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size, growth rate, competitive landscape, and key players. This comprehensive analysis helps business organizations to gain a holistic understanding of market dynamics & make informed decisions.
2. This report also highlights current market trends & future projections, allowing business organizations to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
3. Global Amyotrophic Lateral Sclerosis Treatment Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, business organizations can develop strategies to minimize risks & optimize their operations.

*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.